Insamo
Chippendale, AU · Founded 2022 · Delaware corporation · 6 known investors
Find your way into Insamo
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.
Founders & leadership
Board
CG
MH
Investors · 6
Reported raises · per SEC filings
Form D private placements$11.8M disclosed across 2 rounds · 2023
▶$2.3MraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2.3MraisedDec 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- COREY GOODMANDirector
- TOBY PASSIOURAExecutive Officer, Director
- MATT HERSHENSONDirector
- GLEN MCINTYREExecutive Officer, Director
- TIMOTHY CRAVENExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$9.5MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
▶$9.5MraisedMar 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- COREY GOODMANDirector
- TIMOTHY CRAVENExecutive Officer, Director
- MATT HERSHENSONDirector
- TOBY PASSIOURAExecutive Officer, Director
- GLEN MCINTYREExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $9.5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Sangamo Therapeutics9 shared keywordsSangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.
Avaamo4 shared keywordsAvaamo builds a conversational AI platform for enterprise that deploys autonomous agents across healthcare, customer support, and employee support operations. The platform executes end-to-end workflows in hospitals, contact centers, and HR departments to reduce manual administrative work.
Ensoma4 shared keywordsEnsoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Insamo for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Insamo do?
- Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.
- Who are Insamo's investors?
- Insamo's investors include Civilization Ventures Management, Llc, MRL Ventures Fund, Playground Global, venBio Partners, Axial VC, venBio Global Strategic.
- How much funding has Insamo raised?
- Insamo has disclosed $11.8M raised across 2 rounds.
- Where is Insamo headquartered?
- Insamo is headquartered in Chippendale, AU.